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Abstract
In a recent research article in Arthritis Research and Therapy
(‘Analysis of C204 and the C4 binding protein in the MRL/lpr
mouse’), Wenderfer and colleagues report that deficiency in C4
binding protein, a down-regulator of the classic pathway of
complement, does not affect the development of autoimmune
disease. These data support the earlier finding that the alternative
pathway, and not the classic pathway, drives disease progression.
However, in a milder variant of the MRL/lpr model, the lpr/lpr
mouse, classic pathway deficiency does contribute toward renal
pathology and more severe disease. In this editorial we discuss the
factors that may cause such a discrepancy.
In a previous issue of Arthritis Research and Therapy,
Wenderfer and colleagues [1] analysed the C4 and the C4
binding protein in the MLR/lpr mouse, a well-studied model of
immune complex disease with autoimmune tissue damage
[2]. The lpr mutation confers a defect in Fas, with resulting
failure of cellular apoptosis, and the MRL defects predispose
the mouse to the development of autoimmunity. At an early
age these mice develop massive lymphadenopathy, lupus like
antibodies, and severe tissue damage.
Organ pathology results, in part, from the formation and
organ deposition of immune complexes, the activation of
complement, and consequent tissue damage. Previous work
has shown that much of this damage is a result of alternative
complement pathway (AP) activation [3]. Cross-breeding
MRL/lpr mice with complement factor B deficient animals,
defective in activation and function of the AP but with the
classic complement pathway (CP) intact, leads to ameliora-
tion of symptoms, decreased glomerulonephritis, vasculitis,
tissue damage and decreased lethality. The CP has not been
shown to be a major pathway for complement mediated
tissue damage in MRL/lpr mice.
Wenderfer and colleagues [1] have carried this analysis
further by examining the effect of C4 binding protein (C4bp)
deficiency in the MRL/lpr model. Their methodology was
similar to studies of factor B deficiency. The mutation for
C4bp was bred into MRL/lpr mice and these doubly inbred
animals were compared to the parent strain MRL/lpr in terms
of organ pathology, complement activation, and lethality.
It is known that C4bp is a control protein of the CP and plays
little or no role in AP activation [4]. C4bp has a number of
actions: it binds primarily to C4b to inhibit the continued
activation of the CP; it serves to increase the degradation of
the CP C3 convertase, consisting of C4b and C2a, and
thereby decrease the activity of the convertase; it acts as a
co-factor for the degradation of C4b to C4d with comple-
ment factor I; and C4bp has been shown more recently to
interact with CD40 as well as CD154 in human in vitro
models, although the details of these interactions are still not
clear [5,6].
In the study by Wenderfer and colleagues [1], the authors
report that deficiency in C4bp made little difference to
survival, organ pathology, and the extent of autoimmunity in
MRL/lpr animals. This further supports the central role of the
AP in contrast to the CP. An interesting question relates the
findings in this paper and the findings of Prodeus and
colleagues [7]. These authors studied the effect of targeting
the genes for complement proteins C4 and C3 and the
complement receptors CD35 and CD21 in the closely
related lpr/lpr model. In the absence of the MRL abnormalities
and on the C57/B6 background, these mice develop mild
autoimmune disease. They reported that when the gene for
C4 or CD21/CD35 was deleted in the lpr/lpr model, but not
the gene for C3, there was a marked increase in disease
activity and lethality. They reasoned that in this and other
disease models, C4 and CD35/CD21 participate in tolerance
induction. Presumably, if the gene for C4bp was of great
importance in down-regulating the CP, this pathway might be
up-regulated upon gene deletion and lead to an increase in
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tolerance induction. However, this was not the case. On the
other hand, C4 levels are low in the MRL/lpr model, perhaps
preventing C4bp from regulating C4 and CP activity.
The MRL/lpr model may not be the optimal choice for
studying the function of C4bp in mediating tolerance
induction. The abnormality is present in mice on an H-2k
background, which is known to be associated with very low
serum C4, as recognized by Wenderfer and colleagues [1].
The MRL/lpr mouse has a defect in Fas mediated apoptosis,
one of the multiple checkpoints in the immune response that
leads to the deletion of strongly self-reactive lymphocytes [8].
On the MRL background this defect predisposes to severe
autoimmunity. The animals have massive enlargement of
lymphoid organs.  Perhaps the modulating effects contributed
by the CP are not evident when massive stimulation of self
reactive lymphocytes is induced.
The finding that C4bp deficient MRL/lpr animals have no
alteration in autoimmune manifestations of disease confirms
the observation that, in this model, the AP plays the dominant
role in tissue deposition of immune complexes and organ
damage. It is known that in many situations, the AP is
activated by the CP, and the AP provides most of the
anaphylotoxins, C3a and C5a, as well as most of the C3
deposited in tissue. In the MRL/lpr model, there may be such
high levels of circulating immune complexes in these animals
that the AP does not require the CP for optimal activation.
More studies should define these issues.
The detailed paper by Wenderfer and colleagues clearly
shows that C4bp cannot control the development of
autoimmunity in the MRL/lpr model and leads the way to
further studies that may help us understand how individual
complement pathways contribute to either tolerance or
autoimmunity.
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